tbuckley/cabot-search huggingface dataset:
ERRATUM
Authors: Archibald Hill, Tom Thomas, Edward Reilly, Bruce Winter
Journal: British Journal of Sports Medicine (1976)

In this issue of the journal, the ancient origins of sports medicine are discussed in the paper by Don Masterson, who describes clinical facilities and sports injuries in the time of the ancient Greek civilisation.He points out that there was little development of sports medicine, or indeed of medicine of any kind, for some three thousand years.Scientific anatomy made large strides after the Renaissance, but physiology remained virtually a subject remote from experi- mental study until the close of the 19th century.With the beginning of the present century, physiology developed rapidly, taking advantage of related sciences such as electronics, chemistry, and pharmacology.Most effort was concentrated upon the study of the normal man and animal, and upon the infra-normal -the diseased patient.Very few people paid any attention to the study of the supra-normal, though such study could give a set of physiological parameters that could be regarded as the ideal for the fit man.Eventually a few physiologists extended their field of study to include the very fit, and the response of the very fit to severe exercise stresses that the untrained man could not undergo.
Runaway Children
Authors: William M. Schmidt
Journal: JAMA (1975)

ADOLESCENTS and children are running away from home, hitting the road, living on the street, more than ever before. Evidence of this has been brought out before the Subcommittee to Investigate Juvenile Delinquency of the Senate Committee on the Judiciary and confirmed by the experience of private agencies and studies such as that of the Massachusetts Committee on Children and Youth. It is not a new thing for young persons to run away from home. In years past, some ran away to make their fortune, some to find work, some because of family crisis. A 17th century example is that of one John Dane, a young Englishman whose father "toke a stick and basted me... [when] I went to a dansing scoll to larne to dans." John took off for New England, where after a time "he was joined by his parents and reconciled to them" (Bremner R (ed):<i>Children</i>
Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Advanced Colorectal Cancer Meta-Analysis Project.
Journal: Journal of Clinical Oncology (1994)

PURPOSE Even though fluorouracil (5FU) remains the standard treatment of advanced colorectal cancer, almost 90% of patients treated with 5FU alone do not achieve an objective response to chemotherapy. Biochemical modulation of 5FU by methotrexate (MTX) is an attempt to increase the sensitivity of tumor cells to 5FU. However, despite the inclusion of several hundreds of patients in randomized clinical trials, no definitive evidence is available on the clinical benefit of 5FU/MTX over 5FU alone. A meta-analysis was performed to assess this benefit objectively and quantitatively for tumor response rate and overall survival. DESIGN The meta-analysis was based on individual data of 1,178 patients included in eight randomized clinical trials comparing 5FU alone with 5FU/MTX. Patient data were provided by all principal investigators. The analyses were performed by an independent secretariat, and then discussed with all collaborators. RESULTS Tumor response rate was 10% for patients allocated to 5FU alone (complete response [CR] rate, 2%; partial response [PR] rate, 8%) compared with 19% for patients allocated to 5FU/MTX (CR rate, 3%; PR rate, 16%). This difference was highly significant, with an overall response odds ratio (OR) of 0.51 (95% confidence interval [CI], 0.37 to 0.70) (P &lt; .0001). Median overall survival times were 9.1 months and 10.7 months in the 5FU-alone and 5FU/MTX groups, respectively. This difference was also statistically significant, with an overall survival OR of 0.87 (95% CI, 0.77 to 0.98) (P = .024). Logistic regression model and Cox regression model showed that performance status and randomized treatment were the only two significant predictors of tumor response and survival. CONCLUSION It is concluded that the modulation of 5FU by MTX doubles the response rate to 5FU, and yields a small improvement in survival.
Clinical Lectures Delivered at University College Hospital
Authors: J. Taylor
Journal: BMJ (1843)

Anasarca-Albuminaria-Morbus cordis-Pleutritis- Pneumonia-Epilepsy-Phthisis-Symptoms cha- racterising dropsy from Bright's disease-Secondary inflammations unattended by active symptoms -Epilepsy accompanied by dulnesq of intellect and irritability of temper, another efect of Bright's disease-Urea found in large quanttity in the blood -Causes-Treatment-Cure of the dropsy-S'udden disappearance of friction sound-Diminution of the quantity of urea in the blood, and removal of the head symptoms.
ERRATUM
Authors: Rob Pieters, Martin Horstmann
Journal: Journal of Clinical Oncology (2008)

In the Results section, under Accrual by Age Group, the second sentence indicated that 80.7% of patients were accrued onto trials, whereas it should have been 37.9% as follows:"Overall, 37.9% of Maryland pediatric and adolescent incident patients with cancer were accrued onto treatment trials."In Table 3, under % Patients Accrued by Sex Within Race/Ethnic Group, 60.1% was given for White females, whereas it should have been 60.7%.The online version has been corrected in departure from the print.
Abstract 16966: Effect of Adding Ezetimibe to Statins versus Statin Monotherapy in Cardiovascular Risk Reduction in Patients With Coronary Artery Disease - A Meta-analysis
Authors: Dahlia Banerji, Yasir Akram, Sandeep Somalaraju, Rishi Bajaj, Luigi Pacifico
Journal: Circulation (2015)

Introduction: Statin therapy has been proven to reduce LDL levels and the risk of cardiovascular events. We sought to evaluate the incremental role of Ezetimibe in addition to on-going Statin therapy to assess changes in lipid profile and cardiovascular events. Methods: A comprehensive search in Medline Indexed and Non-indexed was performed to search for randomized controlled trials that examined the role of Ezetimibe plus Statins compared to Statin monotherapy on lipid profile and cardiovascular event rate in patients with coronary artery disease (CAD). We used the mean change for continuous variables and event rates for dichotomous variables for calculating p- values. Results: We included a total of 17 Randomized Control Trials (RCTs) with 22,603 patients, in our meta-analysis. Among these, 15 studies assessed biochemical improvement, whereas 2 RCTs with 18,186 patients evaluated the clinical outcomes. Summary effects were estimated using random effects model. The cumulative estimate showed that addition of Ezetimibe to Statins resulted in an overall mean reduction of total cholesterol (mean change -14.69 mg/dL, 95% CI -18.03, -10.34, p &lt;0.00001), LDL (mean change -12.92 mg/dL, 95% CI -15.5, -12.34, p &lt;0.00001), and triglycerides (mean change -9.94 mg/dL, 95% CI -13.33, -6.55, p &lt;0.00001). However, there was no significant improvement in HDL level. There was also an 11% reduction in mortality with Ezetimibe addition (Odds Ratio 0.89, 95% CI 0.82, 0.96, p =0.002). ConclusioN: In conclusion, addition of Ezetimibe to a Statin in patients with CAD results in a significant reduction in total cholesterol, LDL and triglycerides and also demonstrates a significant mortality benefit.
Mental Stress—Induced Myocardial Ischemia and Cardiac Events
Authors: Wei Jiang
Journal: JAMA (1996)

<h3>Objective.</h3> —To assess the clinical significance of mental stress—induced myocardial ischemia in patients with coronary artery disease (CAD). <h3>Design and Setting.</h3> —Cohort study in outpatients in a tertiary care teaching hospital assessed at baseline and followed up for up to 5 years. <h3>Subjects.</h3> —A total of 126 volunteer patients (112 men, 14 women; mean age, 59 years) with documented CAD and exercise-induced myocardial ischemia. <h3>Outcome Measures.</h3> —Patients underwent baseline mental stress and exercise testing using radionuclide ventriculography and 48-hour Holter monitoring. Patients were subsequently contacted by mailed questionnaires or telephone to document cardiac events, including death, nonfatal myocardial infarction, and cardiac revascularization procedures. Logistic regression and Cox proportional hazards models were used to examine the prognostic value of the ischemic measures after adjusting for such potential confounding factors as age, baseline left ventricular ejection fraction (LVEF), and history of myocardial infarction. <h3>Results.</h3> —Twenty-eight patients (22%) experienced at least 1 cardiac event. Baseline mental stress—induced ischemia was associated with significantly higher rates of subsequent cardiac events (odds ratio, 2.8; 95% confidence interval [CI], 1.0-7.7;<i>P</i>&lt;.05). The LVEF change during mental stress was significantly related to event-free survival (risk ratio [RR], 2.4; 95% CI, 1. 12-5. 14;<i>P</i>=.02), controlling for age, history of prior myocardial infarction, and baseline LVEF. This relationship remained significant after controlling for electrocardiogram (ECG)—defined ischemia during exercise (RR, 2.2; 95% CI, 1.01-4.81;<i>P</i>&lt;.05). The RR for ECG-defined ischemia during exercise testing was 1.9 (95% CI, 0.95-3.96;<i>P</i>=.07) and the RR for ambulatory ECG ischemia was 0.75 (95% CI, 0.35-1.64;<i>P</i>=.47). <h3>Conclusions.</h3> —The presence of mental stress—induced ischemia is associated with significantly higher rates of subsequent fatal and nonfatal cardiac events, independent of age, baseline LVEF, and previous myocardial infarction, and predicted events over and above exercise-induced ischemia. These data suggest that the relationship between psychological stress and adverse cardiac events may be mediated by the occurrence of myocardial ischemia. (<i>JAMA</i>. 1996;275:1651-1656)
Gallstones
Authors: Donald M. Small
Journal: New England Journal of Medicine (1968)

A RECENT editorial in the Journal 1 pointed out that despite the frequency of gallstones in the United States, research concerning their cause has lagged far behind that in many less prevalent disorders. The purpose of this report is to reclassify and summarize mechanisms of both clinical and experimental gallstone formation and perhaps to suggest direction for further research. The references have been chosen because of the completeness of their discussion or bibliography.For nearly a century and a half stasis, obstruction and inflammation have been mentioned in the literature as etiologic mechanisms in cholelithiasis.2 Although these concepts are important and . . .
FRI0037 IL-33 is over-expressed in the inflamed arteries of patients with giant cell arteritis
Authors: F. Ciccia, G. Guggino, A. Rizzo, A. Giardina, R. Alessandro, C. Salvarani, G. Triolo
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Giant-cell arteritis (GCA) is an inflammatorydisease of blood vessels most commonly involving large and medium arteriesof the head. Interleukin-33 (IL-33), a member of the IL-1 cytokine family [6], is a recently described novel activator of endothelial cells (ECs) which promotes adhesion molecules and proinflammatory cytokine expression in the endothelium, angiogenesis and vascular permeability <i>in vitro</i> and <i>in vivo</i> <h3>Objectives</h3> To study the expression of IL-33 and to evaluate its relationship with macrophage polarization in artery biopsy specimens from patients with giant cell arteritis (GCA). <h3>Methods</h3> IL-33 and ST2 tissue distribution was evaluated by immunohistochemistry. iNOS and CD163 were also used by immunohistochemistry to evaluate the M1 and M2 polarization, respectively. Quantitative gene expression analysis of IL-33, Th2-related transcription factor STAT6, Th2 cytokines (IL-4, IL-5, IL-25) and IFN-g was performed in artery biopsy samples obtained from 20 patients with GCA and 15 controls. Five additional patients who had received prednisone when the temporal artery biopsy was performed were also enrolled. <h3>Results</h3> IFN-g and IL-33 were significantly over-expressed in the inflamed arteries of GCA patients. IL-33 over-expression was not accompanied by a concomitant increase of Th2 cytokines. Neovessels scattered through the inflammatory infiltrates were the main sites of IL-33 expression. The expression of IL-33 receptor ST2 was also increased in GCA patients. Arteries from glucocorticoid-treated patients had a lower expression of IL-33. IL-33 expression was accompanied by a clear M2 macrophages polarization. <h3>Conclusions</h3> This is the first study demonstrating that expression of IL-33 and its receptor ST2 are increased in the inflamed arteries of GCA patients and appears to be suppressed in glucocorticoid treated patients. IL-33 in the inflamed arteries could act earlier in the artery inflammation promoting angiogenesis, vascular leakage and tissue infiltration by inflammatory cells. <h3>Disclosure of Interest</h3> None Declared
The Role of Inflammatory Mediators on Hepatitis B Virus Surface Expression in A Transgenic Mouse Model
Journal: Hepatology (1994)

We have recently reported that administration of recombinant tumor necrosis factor–alpha to hepatitis B virus transgenic mice reduces the hepatic steadystate content of HBV–specific mRNA by up to 80% in the absence of liver cell injury. In the current study, we analyzed the regulatory effects of several other inflammatory cytokines in the same transgenic model system. Hepatic HBV mRNA content was reduced by up to 90% following administration of a single noncytopathic dose (100,000U) of interleukin–2. Comparable effects were produced by administration of alpha and beta interferons, but only after multiple injections of at least 500,000U per mouse. Importantly, the regulatory effect of IL–2 was completely blocked by the prior administration of antibodies to tumor necrosis factor–α, which did not block the effect of IFN–α or IFN–β. In contrast to these observations, recombinant IFNg, IL–1, IL–3, IL–6, TNF–β, transforming growth factor–β and granulocyte–monocyte colony stimulating factor were inactive in this system. These results suggest that selected inflammatory cytokines can down–regulate HBV gene expression in vivo by at least two pathways, one that is dependent on TNF–α and another that is not. These results imply that antigen–nonspecific products of the intrahepatic HBV–specific inflammatory response may contribute to viral clearance or persistence during HBV infection.
HIV co-infection and risk of morbidity and mortality in HCV patients treated by DAA
Authors: Mathieu Chalouni, Stanislas Pol, Philippe Sogni, Helene Fontaine, Karine Lacombe, Jean-Marc Lacombe, Laure Esterle, Camille Gilbert, Dorival Celine, Dominique Salmon-Ceron, Fabrice Carrat, Linda Wittkop
Journal: Journal of Hepatology (2020)
Leads from the MMWR. Non-A, non-B hepatitis associated with a factor IX complex infused during cardiovascular surgery--Arizona
Journal: JAMA (1986)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Retrospective Analysis of Pathological Response in Colorectal Cancer Liver Metastases Following Treatment with Bevacizumab: Updated Findings
Authors: D Smith, M Rouyer, E Mitry, E Francois, A Monnereau, A Sa-Cunha, J Jove, P Noize, N Moore, A Fourrier-Réglat, E Maccaroni, R Giampieri, M Scartozzi, M Prete, A Bittoni, L Faloppi, M Bianconi, S Cascinu
Journal: Annals of Oncology (2012)
Abstract 4725: Efficacy of a new small-molecule inhibitor of histone deacetylase 6 (HDAC6) in preclinical models of B-cell lymphoma and acute myeloid leukemia
Authors: Lorea Villanueva, Montserrat Perez-Salvia, Eneko Aldaba, Yosu Vara, Myriam Fabre, Cristina Ferrer, Carme Masdeu, Aizpea Zubia, Eider San Sebastian, Dorleta Otaegui, Pere Llinàs-Arias, Margalida Rosselló-Tortella, María Berdasco, Fernando Setien, Catia Moutinho, Alberto Villanueva, Eva González-Barca, Josep Muncunill, José Tomás Navarro, Miguel Ángel Piris, Fernando Cossio, Manel Esteller
Journal: Cancer Research (2019)

Abstract Histone deacetylase 6 (HDAC6) is a protein modifier that is an increasingly attractive pharmacological target. Interestingly, the observation that the HDAC6 knock-out mouse is not lethal, in contrast to those undergoing complete loss of class I, II and III HDACs, suggests that specific HDAC6 inhibitors may be better tolerated than pan-HDAC inhibitors or drugs that target the other HDAC classes. In this regard, the compound ACY-1215 (Rocilinostat), the described selective HDAC6 inhibitor, is undergoing clinical trials for the treatment of multiple myeloma. Taking into account the previous information about HDAC6 inhibitor structures, the structural differences between HDAC6 and other HDAC isoforms and also the structural information of other developed HDAC inhibitors, we have previously designed and synthesized a new potential HDAC6 selective inhibitor, QTX125 with growth inhibitory effects in mantle cell lymphoma (MCL) cell lines, mouse models and ex vivo treatment of primary samples obtained from patients with MCL. Herein, we have extended these findings to show that the newly identified HDAC6 inhibitor QTX125 is also able to inhibit the growth of preclinical models of other B-cell lymphomas such as follicular lymphoma and Burkitt’s cell lymphoma, but also of acute acute myeloid leukemia. In addition beyond a-tubulin, a well known HDAC6 target, we have developed a pharmacological and proteomic screening to identify other proteins modified by HDAC6 that can contribute to the described lymphoma and leukemia phenotypes. Citation Format: Lorea Villanueva, Montserrat Perez-Salvia, Eneko Aldaba, Yosu Vara, Myriam Fabre, Cristina Ferrer, Carme Masdeu, Aizpea Zubia, Eider San Sebastian, Dorleta Otaegui, Pere Llinàs-Arias, Margalida Rosselló-Tortella, María Berdasco, Fernando Setien, Catia Moutinho, Alberto Villanueva, Eva González-Barca, Josep Muncunill, José Tomás Navarro, Miguel Ángel Piris, Fernando Cossio, Manel Esteller. Efficacy of a new small-molecule inhibitor of histone deacetylase 6 (HDAC6) in preclinical models of B-cell lymphoma and acute myeloid leukemia [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4725.
“Continuous fat-free mass decline in COPD: fact or fiction?” Erica P.A. Rutten, Martijn A. Spruit, Merry-Lynn N. McDonald, Stephen Rennard, Alvar Agusti, Bartolome Celli, Bruce E. Miller, Courtney Crim, Peter M.A. Calverley, Corrine Hanson, William MacNee, Frits M.E. Franssen, Lowie Vanfleteren and Emiel F.M. Wouters on behalf of the ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points) Investigators. <i>Eur Respir J</i> 2015; 46: 1496–1498.
Journal: European Respiratory Journal (2016)
Editorial
Authors: M Robaszkiewicz
Journal: Endoscopy (2018)

Comme chaque année, vous trouverez dans ce numéro d'Endoscopy les résumés des travaux relatifs à l'endoscopie retenus pour présentation aux Journées Francophones d'Hépato-gastro-entérologie et d'Oncologie Digestive (JFHOD) 2018. Le comité de sélection a enregistré un record de soumissions cette année avec pas moins de 165 résumés et 19 vidéos soumis. Ce nombre témoigne une nouvelle fois du dynamisme de la recherche francophone en endoscopie digestive.
Les tumeurs du cerveau.
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Rubella in mother and congenital cataracts in child. Comparative data in periods with and without epidemics from 1957 to 1964
Authors: M. Siegel
Journal: JAMA (1968)

A prospective study of virus diseases occurring in pregnant women from 1957 to 1964 and a concurrent survey of hospital records revealed a fourfold increase in the number of cases of congenital cataracts following the widespread epidemic of 1964, as compared to the incidence in previous years in which no epidemic of rubella occurred. This increase was related to a greater number of cases of rubella in pregnant women and to a higher rate of occurrence of cataracts among the offspring of those mothers affected within the first eight weeks of gestation. The increased risk that congenital cataracts would occur suggests that there may have been an alteration in the capacity of the rubella virus in 1964 to injure human fetal lens tissue. Preliminary findings on the occurrence of congenital heart disease suggest that the incidence of other major defects in offspring of women who contracted rubella during pregnancy in a year in which a severe epidemic occurred may also rise.